ATE474558T1 - Pharmazeutische formulierungen mit irbesartan - Google Patents

Pharmazeutische formulierungen mit irbesartan

Info

Publication number
ATE474558T1
ATE474558T1 AT07380332T AT07380332T ATE474558T1 AT E474558 T1 ATE474558 T1 AT E474558T1 AT 07380332 T AT07380332 T AT 07380332T AT 07380332 T AT07380332 T AT 07380332T AT E474558 T1 ATE474558 T1 AT E474558T1
Authority
AT
Austria
Prior art keywords
pharmaceutical formulations
formulations containing
containing irbesartan
irbesartan
diuretic
Prior art date
Application number
AT07380332T
Other languages
English (en)
Inventor
Perez Marino Gonzalez
Perez Carmen Ubeda
Martin Ignacio Diez
Original Assignee
Lesvi Laboratorios Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lesvi Laboratorios Sl filed Critical Lesvi Laboratorios Sl
Application granted granted Critical
Publication of ATE474558T1 publication Critical patent/ATE474558T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT07380332T 2007-11-28 2007-11-28 Pharmazeutische formulierungen mit irbesartan ATE474558T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07380332A EP2065035B1 (de) 2007-11-28 2007-11-28 Pharmazeutische Formulierungen mit Irbesartan

Publications (1)

Publication Number Publication Date
ATE474558T1 true ATE474558T1 (de) 2010-08-15

Family

ID=39356685

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07380332T ATE474558T1 (de) 2007-11-28 2007-11-28 Pharmazeutische formulierungen mit irbesartan

Country Status (7)

Country Link
US (2) US20090136571A1 (de)
EP (1) EP2065035B1 (de)
AT (1) ATE474558T1 (de)
DE (1) DE602007007968D1 (de)
ES (1) ES2349317T3 (de)
PL (1) PL2065035T3 (de)
PT (1) PT2065035E (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103040841B (zh) * 2013-01-09 2014-04-30 南京正大天晴制药有限公司 一种含厄贝沙坦和氢氯噻嗪的药物组合物
CN105078913B (zh) * 2014-05-22 2018-02-27 山东司邦得制药有限公司 一种厄贝沙坦片及其制备方法
JP6668666B2 (ja) * 2015-10-05 2020-03-18 ニプロ株式会社 イルベサルタンを含有する医薬組成物及びその製造方法
CN113648281B (zh) * 2021-09-24 2023-01-17 宁夏医科大学 一种多晶型厄贝沙坦纳米混悬液及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639168A (en) * 1969-04-29 1972-02-01 Sucrest Corp Direct compression vehicles
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
TW201738B (de) 1990-03-20 1993-03-11 Sanofi Co
FR2725987B1 (fr) 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
FR2780403B3 (fr) 1998-06-24 2000-07-21 Sanofi Sa Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
TR200301553A1 (tr) 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
JP4880591B2 (ja) 2004-06-04 2012-02-22 テバ ファーマシューティカル インダストリーズ リミティド イルベサルタンを含む医薬組成物
ES2259909B1 (es) 2005-02-28 2007-06-16 Inke, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de su intermedio de sintesis.
DE102005031577A1 (de) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
EP1806130B1 (de) 2006-01-09 2010-03-31 KRKA, D.D., Novo Mesto Irbesartan enthaltende feste Zubereitung
US20090030052A1 (en) 2006-02-17 2009-01-29 Alembic Limited Pharmaceutical tablet compositions containing irbesartan

Also Published As

Publication number Publication date
ES2349317T3 (es) 2010-12-29
EP2065035A1 (de) 2009-06-03
US20090136571A1 (en) 2009-05-28
EP2065035B1 (de) 2010-07-21
PL2065035T3 (pl) 2011-02-28
DE602007007968D1 (de) 2010-09-02
PT2065035E (pt) 2010-10-04
US20110223211A1 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
CY1126116T1 (el) Φαρμακευτικες συνθεσεις αποτελουμενες απο νιλοτινιμπη
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
BRPI0814666A2 (pt) composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
MA32812B1 (fr) Composition pharmaceutique d'un inhibiteur puissant du vhc pour une administration orale
PL2364983T3 (pl) Nowa pochodna tricykliczna lub jej farmaceutycznie dopuszczalne sole, sposób jej wytwarzania, oraz zawierająca ją kompozycja farmaceutyczna
ECSP099442A (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
MX2009013501A (es) Compuestos piperidinicos y sus usos.
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
EA201170512A1 (ru) Композиция для перорального введения
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
CL2011003371A1 (es) Composicion farmaceutica de dosis fija, oral, solida y estable que comprende irbesartan, besilato de amlodipino y excipientes; procedimientos de preparacion; uso en el tratamiento de la hipertension.
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
EP2062579A4 (de) Feste pharmazeutische zusammensetzung zur oralen verabreichung mit optisch stabilem ramosetron
WO2010049449A3 (en) Novel salts of sunitinib
MA32406B1 (fr) Composés contenant de l'azote tricyclique et utilisation de ceux-ci comme antibactériens
MX2009003169A (es) Derivados de sulfonamida.
PH12012500992A1 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
ATE474558T1 (de) Pharmazeutische formulierungen mit irbesartan
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
ATE479427T1 (de) Pharmazeutische zusammensetzung mit candesartan- cilexetil
UY29134A1 (es) Sulfonamidas sustituidas por derivados de bencimidazol, composiciones que la contienen, procedimiento de preparacion y aplicaciones
BRPI0808377B8 (pt) composto, composição e uso de um composto
WO2006077024A3 (en) 5-aminoindole derivatives

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties